The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Obesity drugmaker Novo Nordisk has today downgraded its 2025 sales forecast, ending a four-year stretch of steady guidance ...

Shares of Septerna Inc. were soaring in early Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

It’s illegal to advertise prescription drugs. Novo Nordisk, which makes Ozempic and Wegovy, has not named any drugs in its ...

Novo Nordisk shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later this ...

Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Novo Nordisk shares dropped 5% in early trading on Monday after Eli Lilly released new trial data showing its weight loss ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...